12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Suvorexant regulatory update

Merck said FDA accepted for review an NDA for suvorexant to treat insomnia. The pharma would not...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >